Dr. Robert H. Gross, MD
Ophthalmology (Ophthalmology Physician)
3815 E Bell Rd, Suite 2500
Phoenix, AZ 85032
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Geffen School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 587
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of California, Geffen School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
AZ license 24084
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Cornea and Cataract Consultants of Arizona PC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 587
- Services billed
- 1,509
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 803 | 426 |
| Established patient office or other outpatient visit, 20-29 minutes | 361 | 258 |
| New patient office or other outpatient visit, 45-59 minutes | 108 | 108 |
| Removal of cataract with insertion of prosthetic lens | 79 | 54 |
| Ultrasound scan of cornea to determine thickness | 68 | 56 |
| Ct scan of cornea | 65 | 50 |
| Measurement of corneal curvature and depth of eye | 43 | 42 |
| Removal of recurring cataract in lens capsule using a laser | 40 | 31 |
| Closure of tear duct opening using plug | 30 | 15 |
| Exam of visual field with extended testing | 29 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pred Forte (prednisolone acetate) Other prescribers in Phoenix, AZ | 297 |
| Ofloxacin Other prescribers in Phoenix, AZ | 229 |
| Restasis (cyclosporine) Other prescribers in Phoenix, AZ | 216 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Phoenix, AZ | 198 |
| Ketorolac Tromethamine Other prescribers in Phoenix, AZ | 190 |
| Prednisolone Acetate Other prescribers in Phoenix, AZ | 182 |
| Brimonidine Tartrate Other prescribers in Phoenix, AZ | 182 |
| Loteprednol Etabonate | 113 |
| Difluprednate | 101 |
| Acyclovir Other prescribers in Phoenix, AZ | 94 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 9 payments worth $262 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $98.66 |
|---|---|
| Harrow Eye, LLC | $78.38 |
| Oyster Point Pharma, Inc. | $32.55 |
| Biotissue Holdings Inc. | $28.07 |
| Dompe US, Inc. | $24.58 |
| Food and Beverage | $262 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $93,314 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Oyster Point Pharma, Inc. · Terminated · NCT06400511
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.